ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.35), $0.01 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $7.97 million versus the consensus estimate of $7.48 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.